{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:57:21Z","timestamp":1773982641940,"version":"3.50.1"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cutaneous neurofibromas (cNFs) are benign skin tumours affecting over 95% of individuals with neurofibromatosis type 1 (NF1). Their visible appearance often leads to altered body image, social isolation and discrimination. Although stigma is a well-recognized burden in NF1 and has been identified by the Response Evaluation in Neurofibromatosis and Schwannomatosis consortium as a key outcome subdomain for future cNF clinical trials, no specific tool has been developed to assess stigma in relation to cNFs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To adapt, develop and validate a patient-reported outcome measure (PROM) specifically designed to assess stigma in adults with NF1 and cNFs, and to define its severity strata.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An expert working group including patients with NF1 modified the existing Patient Unique Stigmatization Holistic tool in Dermatology (PUSH-D) (used in chronic dermatoses) to create the 19-item cNF-PUSH-D. Following a pilot phase, a 13-item version was tested and validated through two cross-sectional studies: one in France (n = 224) via the ComPaRe NF1 cohort, and another in the USA (n = 142) via the NF Genetics Cohort. Psychometric properties were evaluated through exploratory and confirmatory factor analyses, Cronbach\u2019s \u03b1 and intraclass correlation coefficients (ICCs). Convergent validity was assessed against the cNF-Skindex, the Generalized Anxiety Disorder (GAD-7) and the nine-item Patient Health Questionnaire (PHQ-9). Severity strata were defined using responses to a stigma anchor item.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cNF-PUSH-D demonstrated excellent reliability (Cronbach\u2019s \u03b1 = 0.941, ICC = 0.939) and strong construct validity. We identified two dimensions: \u2018felt stigma\u2019 and \u2018enacted stigma\u2019. The score correlated significantly with anxiety, depression and quality-of-life measures (all P &amp;lt; 0.001). Severity strata were defined as low (0\u201321), moderate (22\u201332) and high (&amp;gt; 33) stigma (\u03ba = 0.516). A higher number of cNFs (\u2265 100) was significantly associated with greater stigma. Scores were comparable between the US and French cohorts, and measurement invariance testing confirmed that the factorial structure remained consistent across countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The cNF-PUSH-D is the first validated PROM to assess stigma specific to cNFs. It demonstrates strong psychometric properties across international populations and fills a critical gap for ongoing and future clinical trials in NF1. By quantifying stigma, the tool enables better understanding, monitoring and management of this key aspect of the cNF disease burden.<\/jats:p>\n                    <jats:p>An author video to accompany this article is available online.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf479","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:58:53Z","timestamp":1764075533000},"page":"679-688","source":"Crossref","is-referenced-by-count":0,"title":["Stigmatization related to cutaneous neurofibromas in neurofibromatosis 1: development, validation and severity strata of the cNF-PUSH-D"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3528-9804","authenticated-orcid":false,"given":"Laura","family":"Fertitta","sequence":"first","affiliation":[{"name":"Department of Dermatology, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital , Assistance Publique \u2013 H\u00f4pitaux de Paris (AP-HP), 94010 Cr\u00e9teil ,","place":["France"]},{"name":"INSERM, Centre d\u2019Investigation Clinique 1430, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital , Assistance Publique-H\u00f4pitaux Paris (AP-HP), 94010 Cr\u00e9teil ,","place":["France"]},{"name":"INSERM U955, IMRB, 94010, Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita Y","family":"Sarin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford Medicine, Stanford University , Redwood City, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos G","family":"Romo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine , Baltimore, MD ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Bergqvist","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital , Assistance Publique \u2013 H\u00f4pitaux de Paris (AP-HP), 94010 Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1049-0993","authenticated-orcid":false,"given":"Jaishri O","family":"Blakeley","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University School of Medicine , Baltimore, MD ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bastien","family":"Peiffer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital , Assistance Publique \u2013 H\u00f4pitaux de Paris (AP-HP), 94010 Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-6739","authenticated-orcid":false,"given":"Viet-Thi","family":"Tran","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology, H\u00f4tel-Dieu Hospital (AP-HP) , Paris ,","place":["France"]},{"name":"Universit\u00e9 de Paris , CRESS, INSERM, INRA, F-75004 Paris ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Laure","family":"Armand","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital , Assistance Publique \u2013 H\u00f4pitaux de Paris (AP-HP), 94010 Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Moryousef","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital , Assistance Publique \u2013 H\u00f4pitaux de Paris (AP-HP), 94010 Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salah","family":"Ferkal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital , Assistance Publique \u2013 H\u00f4pitaux de Paris (AP-HP), 94010 Cr\u00e9teil ,","place":["France"]},{"name":"INSERM, Centre d\u2019Investigation Clinique 1430, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital , Assistance Publique-H\u00f4pitaux Paris (AP-HP), 94010 Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Le Corvoisier","sequence":"additional","affiliation":[{"name":"INSERM, Centre d\u2019Investigation Clinique 1430, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital , Assistance Publique-H\u00f4pitaux Paris (AP-HP), 94010 Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital , Assistance Publique \u2013 H\u00f4pitaux de Paris (AP-HP), 94010 Cr\u00e9teil ,","place":["France"]},{"name":"INSERM, Centre d\u2019Investigation Clinique 1430, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital , Assistance Publique-H\u00f4pitaux Paris (AP-HP), 94010 Cr\u00e9teil ,","place":["France"]},{"name":"Universit\u00e9 Paris-Est Cr\u00e9teil (UPEC) , 94010 Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Wolkenstein","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital , Assistance Publique \u2013 H\u00f4pitaux de Paris (AP-HP), 94010 Cr\u00e9teil ,","place":["France"]},{"name":"INSERM, Centre d\u2019Investigation Clinique 1430, National Referral Center for Neurofibromatoses (CERENEF), Henri-Mondor Hospital , Assistance Publique-H\u00f4pitaux Paris (AP-HP), 94010 Cr\u00e9teil ,","place":["France"]},{"name":"INSERM U955, IMRB, 94010, Cr\u00e9teil ,","place":["France"]},{"name":"Universit\u00e9 Paris-Est Cr\u00e9teil (UPEC) , 94010 Cr\u00e9teil ,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"2026031913324805000_ljaf479-B1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archderm.141.1.71","article-title":"Prevalence of neurofibromatosis 1 in German children at elementary school enrollment","volume":"141","author":"Lammert","year":"2005","journal-title":"Arch Dermatol"},{"key":"2026031913324805000_ljaf479-B2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A"},{"key":"2026031913324805000_ljaf479-B3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/jmg.26.11.704","article-title":"A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity","volume":"26","author":"Huson","year":"1989","journal-title":"J Med Genet"},{"key":"2026031913324805000_ljaf479-B4","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/gim.2017.215","article-title":"Prevalence of neurofibromatosis type 1 in the Finnish population","volume":"20","author":"Kallionp\u00e4\u00e4","year":"2018","journal-title":"Genet Med"},{"key":"2026031913324805000_ljaf479-B5","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1346-8138.1992.tb03799.x","article-title":"The neurofibromatosis type 1 (NF1) gene: identification and partial characterization of a putative tumor suppressor gene","volume":"19","author":"O\u2019Connell","year":"1992","journal-title":"J Dermatol"},{"key":"2026031913324805000_ljaf479-B6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1172-6-18","article-title":"Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France","volume":"6","author":"Duong","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"2 Suppl 1","key":"2026031913324805000_ljaf479-B7","first-page":"S5","article-title":"Cutaneous neurofibromas: current clinical and pathologic issues","volume":"91","author":"Ortonne","year":"2018","journal-title":"Neurology"},{"key":"2026031913324805000_ljaf479-B8","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/ajmg.a.31422","article-title":"Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases","volume":"140","author":"Page","year":"2006","journal-title":"Am J Med Genet A"},{"key":"2026031913324805000_ljaf479-B9","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/archderm.137.11.1421","article-title":"Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases","volume":"137","author":"Wolkenstein","year":"2001","journal-title":"Arch Dermatol"},{"key":"2026031913324805000_ljaf479-B10","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/jdv.18140","article-title":"Quality of life in neurofibromatosis 1: development and validation of a tool dedicated to cutaneous neurofibromas in adults","volume":"36","author":"Fertitta","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7 Suppl 1","key":"2026031913324805000_ljaf479-B11","first-page":"S25","article-title":"Measuring the Effect of cutaneous neurofibromas on quality of life in neurofibromatosis type 1","volume":"97","author":"Maguiness","year":"2021","journal-title":"Neurology"},{"key":"2026031913324805000_ljaf479-B12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/jamadermatol.2020.5732","article-title":"Evaluation of stigma toward individuals with alopecia","volume":"157","author":"Creadore","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026031913324805000_ljaf479-B13","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.jaad.2018.08.014","article-title":"Stigmatizing attitudes toward persons with psoriasis among laypersons and medical students","volume":"80","author":"Pearl","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026031913324805000_ljaf479-B14","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.jaad.2020.06.060","article-title":"Psoriasis-related stigma and its intersection with intergroup bias in medical students","volume":"84","author":"Fino","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026031913324805000_ljaf479-B15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12916-018-1245-x","article-title":"Out of the silos: identifying cross-cutting features of health-related stigma to advance measurement and intervention","volume":"17","author":"van Brakel","year":"2019","journal-title":"BMC Med"},{"key":"2026031913324805000_ljaf479-B16","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/PRBM.S65578","article-title":"Spiritual and religious aspects of skin and skin disorders","volume":"7","author":"Shenefelt","year":"2014","journal-title":"Psychol Res Behav Manag"},{"key":"2026031913324805000_ljaf479-B17","volume-title":"Stigma: Notes on the Management of Spoiled Identity","author":"Goffman","year":"1986"},{"key":"2026031913324805000_ljaf479-B18","volume-title":"Monstrorum Historia","author":"Aldrovandi","year":"1642"},{"key":"2026031913324805000_ljaf479-B19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/cge.12498","article-title":"The natural history of spinal neurofibromatosis: a critical review of clinical and genetic features","volume":"87","author":"Ruggieri","year":"2015","journal-title":"Clin Genet"},{"key":"2026031913324805000_ljaf479-B20","first-page":"1801","article-title":"Quest for Quasimodo (V. Hugo)","volume-title":"Br Med J (Clin Res Ed)","author":"Cox","year":"1985"},{"key":"2026031913324805000_ljaf479-B21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/13591053231208619","article-title":"Lived experiences of neurofibromatosis type 1 patients: Social life, stigma, and intervention strategies","volume":"29","author":"Aghaei","year":"2024","journal-title":"J Health Psychol"},{"key":"2026031913324805000_ljaf479-B22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13023-023-02629-1","article-title":"Psychosocial implications of rare genetic skin diseases affecting appearance on daily life experiences, emotional state, self-perception and quality of life in adults: a systematic review","volume":"18","author":"Fournier","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"2026031913324805000_ljaf479-B23","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/s10897-016-9944-y","article-title":"The role of appearance in adolescents\u2019 experiences of neurofibromatosis type 1: a survey of young people and parents","volume":"25","author":"Barke","year":"2016","journal-title":"J Genet Couns"},{"key":"2026031913324805000_ljaf479-B24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10880-018-9584-5","article-title":"Lifespan development: symptoms experienced by individuals with neurofibromatosis type 1 associated plexiform neurofibromas from childhood into adulthood","volume":"26","author":"Jensen","year":"2019","journal-title":"J Clin Psychol Med Settings"},{"key":"2026031913324805000_ljaf479-B25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ajmg.a.37987","article-title":"Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis type 1 associated plexiform neurofibromas (pNF) across the lifespan","volume":"173","author":"Lai","year":"2017","journal-title":"Am J Med Genet A"},{"key":"2026031913324805000_ljaf479-B26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/bjd\/ljad397","article-title":"A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials","volume":"190","author":"Fertitta","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026031913324805000_ljaf479-B27","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/j.jid.2023.04.014","article-title":"cNF-Skindex in adults living with neurofibromatosis 1: severity strata in France and validation in United States adults","volume":"143","author":"Fertitta","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2026031913324805000_ljaf479-B28","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/jdv.18641","article-title":"Patient Unique Stigmatization Holistic tool in Dermatology (PUSH-D): development and validation of a dermatology-specific stigmatization assessment tool","volume":"37","author":"Ezzedine","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026031913324805000_ljaf479-B29","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s11136-018-1829-0","article-title":"COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study","volume":"27","author":"Terwee","year":"2018","journal-title":"Qual Life Res"},{"key":"2026031913324805000_ljaf479-B30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jclinepi.2020.04.021","article-title":"COllaborative Open Platform E-cohorts for research acceleration in trials and epidemiology","volume":"124","author":"Tran","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2026031913324805000_ljaf479-B31","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026031913324805000_ljaf479-B32","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","article-title":"Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire","volume":"282","author":"Spitzer","year":"1999","journal-title":"JAMA"},{"key":"2026031913324805000_ljaf479-B33","first-page":"462","article-title":"A new method for the quantitative measurement of the aerobic pectinolytic activity of soils","volume":"99","author":"Kaiser","year":"1960","journal-title":"Ann Inst Pasteur"},{"key":"2026031913324805000_ljaf479-B34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/00131644221075580","article-title":"Assessing essential unidimensionality of scales and structural coefficient bias","volume":"83","author":"Liu","year":"2023","journal-title":"Educ Psychol Meas"},{"key":"2026031913324805000_ljaf479-B35","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0013164412449831","article-title":"Multidimensionality and structural coefficient bias in structural equation modeling: a bifactor perspective","volume":"73","author":"Reise","year":"2012","journal-title":"Educ Psychol Meas"},{"key":"2026031913324805000_ljaf479-B36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF02289113","article-title":"Time-limit tests: estimating their\u00a0reliability and degree of speeding","volume":"16","author":"Cronbach","year":"1951","journal-title":"Psychometrika"},{"key":"2026031913324805000_ljaf479-B37","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1007\/s11136-024-03761-6","article-title":"COSMIN guideline for systematic reviews of patient-reported outcome measures version 2.0","volume":"33","author":"Mokkink","year":"2024","journal-title":"Qual Life Res"},{"key":"2026031913324805000_ljaf479-B38","first-page":"231","article-title":"Quantifying test-retest reliability using the intraclass correlation coefficient and the SEM","volume":"19","author":"Weir","year":"2005","journal-title":"J Strength Cond Res"},{"key":"2026031913324805000_ljaf479-B39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"2026031913324805000_ljaf479-B40","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1037\/met0000152","article-title":"Permutation randomization methods for testing measurement equivalence and detecting differential item functioning in multiple-group confirmatory factor analysis","volume":"23","author":"Jorgensen","year":"2018","journal-title":"Psychol Methods"},{"key":"2026031913324805000_ljaf479-B41","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/jdv.20606","article-title":"On the importance of assessing stigma in dermatological research","volume":"39","author":"Kpenou","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026031913324805000_ljaf479-B42","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1037\/1040-3590.18.1.106","article-title":"The reliability and validity of the Perceived Stigmatization Questionnaire (PSQ) and the Social Comfort Questionnaire (SCQ) among an adult burn survivor sample","volume":"18","author":"Lawrence","year":"2006","journal-title":"Psychol Assess"},{"key":"2026031913324805000_ljaf479-B43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-013-1195-2","article-title":"Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature","volume":"114","author":"Vranceanu","year":"2013","journal-title":"J Neurooncol"},{"key":"2026031913324805000_ljaf479-B44","first-page":"84","article-title":"Neurofibromatosis in Gothenburg, Sweden. III. Psychiatric and social aspects","volume":"2","author":"Samuelsson","year":"1989","journal-title":"Neurofibromatosis"},{"key":"2026031913324805000_ljaf479-B45","first-page":"619","article-title":"Psychological impact of neurofibromatosis type 1: the analysis of interviews with 12 patients with regard to an evaluation of the quality of life","volume":"126","author":"Mauger","year":"1999","journal-title":"Ann Dermatol Venereol"},{"key":"2026031913324805000_ljaf479-B46","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s41687-024-00732-w","article-title":"Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex","volume":"8","author":"Dhaenens","year":"2024","journal-title":"J Patient Rep Outcomes"},{"issue":"7 Suppl. 1","key":"2026031913324805000_ljaf479-B47","first-page":"S32","article-title":"Validating techniques for measurement of cutaneous neurofibromas: recommendations for clinical trials","volume":"97","author":"Thalheimer","year":"2021","journal-title":"Neurology"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf479\/65501189\/ljaf479.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/4\/679\/65501189\/ljaf479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/4\/679\/65501189\/ljaf479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:32:59Z","timestamp":1773941579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/4\/679\/8342553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,26]]},"published-print":{"date-parts":[[2026,3,19]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf479","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,11,26]]}}}